American Journal of
Biomedical Science & Research

www.biomedgrid.com
ISSN: 2642-1747

Review Article

Peptide-Based Therapeutics in Human Female Fertility: Molecular Mechanisms, Translational Evidence, and Clinical Prospects

Mike KS Chan[1,2,3], Michelle BF Wong[1,2], Dmytro Klokol[1,2], Krista Casazza[4] and Jonathan RT Lakey[2,4]*

[1]*European Wellness Academy, Kloster Strasse 205ID, 67480, Edenkoben, Germany*

[2]*European Wellness BioMedical Group, Kloster Strasse 205ID, 67480, Edenkoben, Germany*

[3]*Lincoln University College, Selangor, Malaysia*

[4]*University of California, Irvine, Department of Surgery and Biomedical Engineering, Irvine CA, USA*

***Corresponding author:** Jonathan RT Lakey, Professor Emeritus Departments of Surgery and Biomedical Engineering University of California Irvine, USA.

To Cite This article: *Mike KS Chan, Michelle BF Wong, Dmytro Klokol, Krista Casazza and Jonathan RT Lakey*, Peptide-Based Therapeutics in Human Female Fertility: Molecular Mechanisms, Translational Evidence, and Clinical Prospects. Am J Biomed Sci & Res. 2026 31(5) AJBSR. MS.ID.004075,* **DOI:** 10.3429s7/AJBSR.2026.31.004075

Received: July 07, 2026 **Published:** July 16, 2026

Abstract

Female infertility represents a major global health challenge affecting approximately 10–15% of reproductive-aged women and contributes substantially to declining birth rates, psychosocial burden, and escalating healthcare expenditures worldwide. Female reproductive dysfunction arises from a complex interplay of endocrine dysregulation, ovarian aging, mitochondrial dysfunction, oxidative stress, inflammatory signaling, vascular impairment, and environmental exposures that collectively disrupt folliculogenesis, oocyte competence, implantation, and endometrial receptivity. Conventional therapeutic approaches, including ovulation induction, hormonal replacement, and Assisted Reproductive Technologies (ART), frequently bypass rather than restore the underlying molecular mechanisms responsible for reproductive failure. In recent years, peptide-based therapeutics have emerged as promising biologic regulators capable of modulating cellular signaling pathways governing ovarian physiology, mitochondrial bioenergetics, endocrine homeostasis, angiogenesis, and tissue regeneration. Bioactive peptides function as highly specific signaling molecules that influence gonadotropin signaling, steroidogenesis, mitochondrial metabolism, oxidative stress responses, immune regulation, and extracellular matrix remodeling. Experimental and translational studies demonstrate that peptide therapies may enhance follicular development, improve oocyte mitochondrial function, restore ovarian reserve signaling, promote endometrial receptivity, and mitigate inflammatory injury within reproductive tissues. Particularly promising are mitochondrial-derived peptides, organ-specific peptide complexes, and peptide-rich stem-cell secretomes that regulate pathways involving AMPK, PGC-1α, NRF1, TFAM, VEGF, PI3K/Akt, and sirtuin signaling. Emerging nano-delivery systems further enhance peptide stability, receptor targeting, and bioavailability. Integration of peptide therapeutics with precision medicine, reproductive omics, and AI-guided hormonal monitoring may enable individualized fertility restoration strategies. This review synthesizes current mechanistic, experimental, and translational evidence supporting peptide therapeutics as a next-generation modality in female reproductive medicine.

Keywords: Female infertility, Peptide therapeutics, Ovarian aging, Mitochondrial dysfunction, Oxidative stress, Reproductive endocrinology, Ovarian reserve, Reproductive biotechnology

Introduction

Female reproductive health represents a fundamental determinant of fertility, population sustainability, maternal health, and demographic stability [1]. Infertility affects approximately 10–15% of couples globally, with female factors contributing to nearly half of all cases either independently or in combination with male reproductive dysfunction [2]. Recent epidemiological studies indicate that female infertility is increasing worldwide, driven by delayed childbearing, environmental exposures, metabolic disease, endocrine disruption, and age-associated reproductive decline [3]. Simultaneously, declining fecundity rates across industrialized nations have intensified interest in the biological mechanisms governing ovarian aging and reproductive longevity [4]. Female infertility encompasses a heterogeneous spectrum of disorders involving abnormalities in ovulation, folliculogenesis, oocyte maturation, fertilization, implantation, and endometrial receptivity. Clinically, these conditions include anovulation, luteal phase defects, diminished ovarian reserve, premature ovarian insufficiency, recurrent implantation failure, recurrent pregnancy loss, endometriosis-associated infertility, and age-related reproductive decline. Although these phenotypes are conventionally categorized according to endocrine or anatomical abnormalities, growing evidence indicates that they frequently represent downstream manifestations of interconnected molecular disturbances involving mitochondrial dysfunction, oxidative stress, chronic inflammation, vascular dysregulation, immune imbalance, and epigenetic alterations. Increasingly, female infertility is recognized as a systems-level disorder arising from the convergence of endocrine, metabolic, inflammatory, mitochondrial, and environmental signaling networks rather than isolated dysfunction within a single reproductive organ. The increasing prevalence of Polycystic Ovary Syndrome (PCOS), Endometriosis, Diminished Ovarian Reserve (DOR), Premature Ovarian Insufficiency (POI), obesity-associated infertility, and implantation failure has further underscored the complexity of female reproductive dysfunction and the limitations of current therapeutic approaches [5].

Female reproductive function is regulated through coordinated Hypothalamic–Pituitary–Ovarian (HPO) axis signaling. Pulsatile hypothalamic secretion of Gonadotropin-Releasing Hormone (GnRH) stimulates pituitary release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which orchestrate follicular recruitment, ovarian steroidogenesis, and corpus luteum formation [6]. FSH stimulates granulosa-cell proliferation and aromatase activity, whereas LH regulates theca-cell androgen synthesis and ovulatory signaling pathways. Estradiol, progesterone, Anti-Müllerian Hormone (AMH), inhibins, and activins collectively provide feedback regulation necessary for cyclic reproductive homeostasis [7]. Disruption of these pathways can impair follicular maturation, compromise oocyte competence, alter endometrial receptivity, and ultimately reduce fertility potential [8]. Central to many of these pathological processes is the progressive deterioration of mitochondrial function, which has emerged as a critical determinant of ovarian physiology and reproductive longevity.

Oocytes contain the highest mitochondrial density of any cell type within the human body, reflecting the substantial energetic demands associated with meiotic maturation, fertilization, and early embryonic development [9]. Mitochondrial oxidative phosphorylation generates ATP necessary for spindle assembly, chromosomal segregation, calcium signaling, and embryogenesis [10]. However, mitochondria also represent a major intracellular source of Reactive Oxygen Species (ROS), which at physiological concentrations participate in ovulation and signaling processes but become deleterious when produced excessively [11]. Oxidative stress contributes to mitochondrial DNA damage, spindle abnormalities, chromosomal instability, apoptosis, and accelerated ovarian aging [12]. Importantly, mitochondrial dysfunction and oxidative stress exist within a self-amplifying feedback loop that progressively impairs oocyte quality and reproductive potential with advancing age [13]. Inflammatory signaling further contributes to female reproductive pathology. Chronic low-grade inflammation has been implicated in PCOS, endometriosis, recurrent implantation failure, obesity-associated infertility, and premature ovarian insufficiency [14]. Pro-inflammatory cytokines including Tumor Necrosis Factor (TNF)-α, Interleukin (IL)-1β, IL-6, and Transforming Growth Factor-beta (TGF-β) disrupt follicular signaling, impair endometrial receptivity, alter angiogenesis, and promote fibrotic remodeling within reproductive tissues [15]. Endometriosis exemplifies the convergence of inflammation, oxidative stress, immune dysregulation, angiogenesis, and mitochondrial dysfunction within the reproductive microenvironment [16].

Environmental and metabolic stressors further amplify these vulnerabilities. Exposure to endocrine-disrupting chemicals, microplastics, heavy metals, pesticides, and air pollutants has been associated with impaired ovarian reserve, menstrual dysfunction, implantation failure, and altered steroidogenesis [17]. Likewise, obesity, insulin resistance, diabetes mellitus, and metabolic syndrome exert profound effects on ovarian physiology through chronic inflammation, altered adipokine signaling, oxidative stress, and dysregulated insulin signaling pathways [18]. These multifactorial influences suggest that female infertility should be understood as a complex systems-biology disorder involving disruption of coordinated endocrine, metabolic, vascular, mitochondrial, inflammatory, and epigenetic networks. Despite advances in reproductive medicine, current therapeutic strategies remain limited. Ovulation induction, gonadotropin stimulation, hormonal replacement, and assisted reproductive technologies such as In Vitro Fertilization (IVF) frequently bypass rather than correct the molecular pathology underlying impaired fertility [19]. Although Assisted Reproductive Therapy (ART) has improved pregnancy rates for many patients, outcomes remain constrained by declining oocyte quality, mitochondrial dysfunction, implantation failure, and age-related reproductive decline [20]. Furthermore, ART procedures impose substantial financial, emotional, and physiological burdens while failing to directly restore reproductive homeostasis [21].

Recent advances in molecular biology, regenerative medicine,

and peptide biotechnology have therefore stimulated increasing interest in bioactive peptides as modulators of reproductive physiology. Peptides are short amino acid signaling molecules capable of regulating endocrine pathways, mitochondrial metabolism, angiogenesis, immune signaling, gene transcription, and cellular stress responses [22]. Unlike conventional pharmacologic agents that broadly alter systemic physiology, peptides frequently exhibit high receptor specificity and operate through endogenous signaling cascades, enabling targeted modulation of dysregulated biological pathways [23]. Peptide-mediated signaling has been implicated in folliculogenesis, steroidogenesis, mitochondrial regulation, implantation, tissue remodeling, and ovarian regeneration [24]. Particularly promising are Mitochondrial-Derived Peptides (MDPs) and organ-specific peptide complexes that regulate mitochondrial biogenesis, oxidative stress resilience, angiogenesis, and tissue repair. Experimental evidence suggests that these peptides activate pathways involving AMP-Activated Protein Kinase (AMPK), peroxisome proliferator–activated receptor gamma coactivator 1-alpha (PGC-1α), Nuclear Respiratory Factor 1 (NRF1), mitochondrial transcription factor A (TFAM), sirtuin signaling pathways, Vascular Endothelial Growth Factor (VEGF), and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling [25]. Each of these pathways are central to ovarian bioenergetics and reproductive aging.

Emerging peptide-rich stem-cell secretomes further suggest the possibility of cell-free regenerative approaches capable of restoring ovarian microenvironment integrity without requiring direct cellular transplantation. The integration of peptide therapeutics into reproductive medicine therefore represents a promising strategy for addressing the molecular drivers of female infertility. By targeting interconnected pathways involving mitochondrial metabolism, endocrine regulation, inflammation, oxidative stress, vascular integrity, and tissue regeneration, peptide-based interventions may offer a mechanistically integrated approach to restoring reproductive homeostasis rather than simply bypassing reproductive dysfunction. Although clinical evidence remains preliminary, accumulating translational and experimental findings support the hypothesis that peptide therapeutics may enhance ovarian function, improve oocyte quality, restore endocrine balance, and optimize reproductive outcomes. Among emerging regenerative approaches, the European Wellness (EW) Biomedical Group has developed a systems-biology framework for female reproductive restoration that integrates organ-specific peptide bioregulators, Mitochondrial Organelle (MO) peptides, Nano-Organo Peptides (NOPs), precursor stem-cell biologics, and secretome-based therapies [26]. Unlike conventional fertility interventions that primarily address isolated hormonal deficiencies or bypass reproductive dysfunction through assisted reproductive technologies, the EW model targets the interconnected endocrine, mitochondrial, vascular, inflammatory, and regenerative pathways that underlie ovarian aging and reproductive decline [27]. This multi-organ strategy emphasizes restoration of Hypothalamic–Pituitary–Ovarian (HPO) axis signaling, mitochondrial bioenergetics, ovarian microvascular integrity, and cellular resilience as fundamental determinants of reproductive competence.

Pathophysiology of Female Infertility: HPO Axis Dysfunction

Normal female reproductive function depends upon tightly coordinated neuroendocrine signaling within the HPO axis [28]. Pulsatile GnRH secretion regulates pituitary gonadotropin release, while ovarian steroid hormones provide dynamic feedback modulation necessary for cyclic ovulation and follicular maturation [29]. Disruption of GnRH pulsatility alters LH and FSH secretion patterns, impairing follicular recruitment, ovulation, and luteal function [30]. Kisspeptin neurons serve as central regulators of GnRH release and integrate metabolic signals including leptin, insulin, and energy status with reproductive signaling [31]. Dysregulation of kisspeptin signaling has been implicated in hypothalamic amenorrhea, obesity-associated infertility, and PCOS. Insulin resistance and hyperinsulinemia further contribute to reproductive dysfunction through amplification of ovarian androgen synthesis and suppression of hepatic Sex Hormone–Binding Globulin (SHBG) production, thereby increasing bioavailable androgens [32]. This endocrine disturbance is particularly relevant in PCOS, where hyperandrogenism disrupts follicular maturation and ovulation. Age-associated reproductive decline is additionally characterized by diminished ovarian reserve, altered gonadotropin sensitivity, declining AMH concentrations, and impaired granulosa-cell function (Table 1).

Table 1: Key Hormones Involved in Female Reproductive Regulation.

Hormone	Function
GnRH	Stimulates pituitary gonadotropin release
FSH	Regulates follicular growth and granulosa-cell activity
LH	Triggers ovulation and steroidogenesis
Estradiol	Regulates follicular maturation and endometrial proliferation
Progesterone	Supports implantation and luteal function
AMH	Marker of ovarian reserve
Inhibin B	Negative feedback regulation of FSH

Oxidative Stress

Oxidative stress represents one of the principal molecular mechanisms underlying ovarian aging and female infertility. Excessive ROS production disrupts redox homeostasis and induces lipid peroxidation, mitochondrial injury, DNA fragmentation, spindle abnormalities, and apoptosis within oocytes and granulosa cells [33]. Biomarkers including 8-hydroxy-2-deoxyguanosine (8-OHdG), malondialdehyde (MDA), and glutathione depletion have been strongly associated with diminished ovarian reserve, endometriosis, implantation failure, and poor IVF outcomes [34]. Oocytes are especially vulnerable to oxidative injury due to prolonged meiotic arrest, high mitochondrial density, and age-associated accumulation of mitochondrial DNA mutations [34]. Oxidative stress interacts bidirectionally with mitochondrial dysfunction, creating a self-perpetuating cycle of ROS amplification, mitochondrial injury, and progressive reproductive decline [35].

Mitochondrial Dysfunction

Mitochondria are fundamental regulators of oocyte maturation, fertilization, and early embryogenesis, serving not only as the primary source of cellular ATP but also as critical signaling organelles governing calcium homeostasis, apoptosis, redox balance, and epigenetic regulation [36]. Human oocytes contain the highest mitochondrial copy number of any cell type in the body, reflecting the extraordinary energetic demands associated with meiotic progression, spindle organization, fertilization, and preimplantation embryo development [37]. Efficient oxidative phosphorylation (Ox Phos), mediated through electron transport chain complexes I–V embedded within the inner mitochondrial membrane, is essential for ATP generation required to support spindle assembly, chromosome alignment, meiotic segregation, cytoplasmic maturation, and subsequent embryo cleavage [38]. Disruption of mitochondrial bioenergetics impairs these highly coordinated processes and contributes directly to aneuploidy, fertilization failure, developmental arrest, and declining embryo competence [9]. Mitochondria also function as dynamic regulators of intracellular signaling pathways that influence reproductive longevity and ovarian reserve maintenance. Physiological mitochondrial activity generates low levels of ROS that participate in ovulatory signaling and oocyte maturation [39]. However, excessive ROS accumulation disrupts redox homeostasis and induces oxidative injury to mitochondrial proteins, lipids, and DNA [40]. Unlike nuclear DNA, mitochondrial DNA (mtDNA) lacks protective histones and possesses relatively limited DNA repair mechanisms, rendering it highly susceptible to oxidative damage and mutational accumulation over time [41]. Age-associated increases in mtDNA deletions, point mutations, and reductions in mitochondrial membrane potential have been strongly correlated with impaired oocyte competence, diminished ovarian reserve, and reduced IVF success rates [42].

Mitochondrial dysfunction and oxidative stress exist within a self-amplifying pathogenic cycle. Defective electron transport chain activity increases electron leakage and ROS generation, which in turn further damages mitochondrial membranes and mtDNA, progressively compromising oxidative phosphorylation efficiency [43]. This bioenergetic deterioration contributes to spindle instability, chromosomal misalignment, telomere shortening, impaired autophagy, and activation of cellular senescence pathways within both oocytes and granulosa cells [10]. Emerging evidence additionally implicates dysregulated mitochondrial dynamics (e.g., impaired mitophagy, altered mitochondrial fusion/fission balance, and defective mitochondrial biogenesis) as central mechanisms underlying ovarian aging and reproductive decline [44]. At the molecular level, maintenance of mitochondrial integrity within ovarian tissues depends upon tightly regulated signaling pathways involving AMP-activated protein kinase (AMPK), sirtuins, peroxisome proliferator–activated receptor gamma coactivator 1-alpha (PGC-1α), nuclear respiratory factors (NRF1/NRF2), and mitochondrial transcription factor A (TFAM), which collectively coordinate mitochondrial biogenesis, oxidative metabolism, antioxidant defense, and metabolic adaptation [45]. Dysregulation of these pathways has been associated with premature ovarian insufficiency, age-related infertility, and impaired embryonic developmental competence [46]. Consequently, mitochondrial dysfunction is increasingly recognized as a primary mechanistic driver of ovarian senescence and declining female fertility.

Recent advances in mitochondrial medicine have expanded beyond conventional antioxidant strategies toward direct modulation of mitochondrial signaling and organelle function. EW has proposed MO therapy as a regenerative platform designed to restore mitochondrial bioenergetics, redox homeostasis, cellular signaling, and regenerative capacity through mitochondrial-derived peptides and organelle-targeted biologics. Given that oocytes possess the highest mitochondrial density of any human cell type and depend upon efficient oxidative phosphorylation for meiotic maturation and embryogenesis, mitochondrial-targeted interventions represent a particularly compelling strategy for reproductive rejuvenation [26]. Mechanistically, MO peptides may influence mitochondrial quality control, mitophagy, AMPK signaling, PGC-1α activation, and oxidative stress resilience, pathways intimately associated with ovarian aging and diminished reproductive competence.

Inflammation and Immune Dysregulation

Chronic inflammatory signaling disrupts the ovarian and endometrial microenvironments necessary for successful reproduction. Activation of NF-κB signaling pathways induces production of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and TGF-β, which impair follicular development, alter steroidogenesis, and compromise implantation [47]. Endometriosis exemplifies the convergence of inflammation, oxidative stress, angiogenesis, fibrosis, and immune dysregulation within female infertility. Elevated inflammatory cytokines and activated macrophages within the peritoneal cavity contribute to oxidative injury, aberrant angiogenesis, and altered endometrial receptivity. Similarly, obesity-associated infertility is characterized by chronic low-grade inflammation, altered adipokine signaling, insulin resistance, and impaired ovarian

steroidogenesis. Disruption of immune tolerance within the endometrium may additionally impair implantation and contribute to recurrent pregnancy loss. Collectively, these interconnected mechanisms underscore the systems-level nature of female infertility and provide a mechanistic foundation for targeted peptide-based therapeutic interventions.

Biological Basis of Peptide Therapeutics

Peptides function as endogenous signaling molecules that regulate cellular physiology through highly specific molecular interactions involving G-Protein–Coupled Receptors (GPCRs), receptor tyrosine kinases, intracellular transcriptional regulators, and mitochondrial signaling pathways. Through these mechanisms, peptides influence endocrine communication, mitochondrial metabolism, angiogenesis, cellular proliferation, apoptosis, immune modulation, extracellular matrix remodeling, and tissue regeneration. Peptide signaling regulates folliculogenesis, ovulation, implantation, angiogenesis, steroidogenesis, and ovarian reserve maintenance. Unlike traditional pharmacologic agents that broadly affect systemic physiology, peptides frequently operate within endogenous signaling cascades, enabling targeted modulation of dysregulated molecular pathways. However, peptide therapeutics are constrained by short biological half-life, proteolytic degradation, limited tissue penetration, and rapid systemic clearance. Consequently, development of nano-carriers, liposomal delivery systems, peptide stabilization strategies, and sustained-release formulations has become critical for clinical translation. Through interactions with G-Protein–Coupled Receptors (GPCRs), receptor tyrosine kinases, and intracellular signaling cascades, peptides influence GnRH pulsatility, pituitary gonadotropin secretion, ovarian steroidogenesis, follicular maturation, and endometrial receptivity [30]. Experimental evidence suggests that peptide-mediated restoration of hypothalamic and pituitary signaling may improve endocrine homeostasis by modulating kisspeptin-GnRH pathways, insulin signaling, and ovarian responsiveness to FSH and LH.[2] Importantly, this approach differs mechanistically from exogenous hormonal replacement because it seeks to restore physiological signaling dynamics rather than bypass endogenous endocrine regulation.

Klotho Signaling as an Emerging Regulator of Reproductive Aging

Klotho has emerged as a pleiotropic longevity-associated protein regulating oxidative stress, inflammation, mitochondrial function, cellular senescence, and metabolic homeostasis. Reduced Klotho expression is increasingly associated with age-related degenerative disorders and biological aging phenotypes [48-50]. Given the central role of oxidative stress and mitochondrial dysfunction in ovarian senescence, Klotho signaling may represent an important upstream regulator of reproductive longevity. European Wellness research programs have highlighted the therapeutic potential of Klotho-centered regenerative strategies as modulators of aging-related pathways relevant to fertility preservation and endocrine resilience.

MDPs have gained increasing attention for their role in preserving ovarian bioenergetics and reproductive longevity. Oocyte maturation and embryogenesis are highly energy-dependent processes requiring efficient mitochondrial oxidative phosphorylation to support spindle assembly, chromosomal segregation, calcium homeostasis, and embryo cleavage [36]. Mitochondrial dysfunction and excessive ROS generation are strongly implicated in ovarian aging, diminished oocyte competence, implantation failure, and declining reproductive outcomes. Mitochondrial-derived peptides such as MOTS-c and humanin regulate ATP synthesis, mitochondrial membrane potential, oxidative phosphorylation efficiency, and antioxidant defense mechanisms through activation of AMPK, sirtuin signaling, peroxisome PGC-1α, NRF1/NRF2, and mitochondrial transcription factor A (TFAM) [51]. These signaling pathways collectively coordinate mitochondrial biogenesis, mitophagy, oxidative metabolism, and metabolic adaptation, thereby improving cellular resilience to oxidative stress and preserving oocyte developmental competence. Emerging evidence further indicates that mitochondrial peptides may attenuate apoptosis and cellular senescence within granulosa cells and ovarian tissues, suggesting a mechanistic role in delaying reproductive aging [13]. Peptide-mediated signaling additionally influences angiogenesis and vascular remodeling within ovarian and endometrial tissues. Adequate vascularization is essential for follicular oxygenation, nutrient delivery, corpus luteum function, and endometrial receptivity. VEGF signaling plays a central role in ovarian follicular angiogenesis and implantation-related endometrial remodeling, while impaired microvascular perfusion has been associated with implantation failure, recurrent pregnancy loss, endometriosis, and diminished ovarian reserve [52]. Bioactive peptides can modulate endothelial proliferation, nitric oxide signaling, extracellular matrix remodeling, and capillary formation through activation of VEGF-mediated pathways and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling [53]. Enhanced angiogenesis may therefore improve follicular microenvironment integrity and optimize the endometrial conditions necessary for embryo implantation and early pregnancy maintenance.

A next-generation evolution of peptide therapeutics involves the development of Nano-Organo Peptides (NOPs) and Mito-Organo Peptides (MOPs). These peptide formulations, developed within regenerative medicine frameworks including European Wellness programs, are derived from organ-specific cellular fractions and are designed to enhance tissue-specific signaling, mitochondrial homeostasis, cellular repair, and metabolic adaptation. NOPs have been proposed to modulate pathways involved in autophagy, oxidative stress regulation, and tissue regeneration, whereas MOPs specifically target mitochondrial function, mitophagy, ATP production, and mitochondrial quality control. Because ovarian aging is characterized by progressive mitochondrial dysfunction, oxidative damage, and stem-cell exhaustion, these peptide platforms may provide biologically integrated approaches for restoration of ovarian function and reproductive resilience [54].

An additional regenerative mechanism involves paracrine signaling mediated by peptide-rich Mesenchymal Stem-Cell (MSC) secretomes. Increasing evidence suggests that many of the regenerative effects traditionally attributed to stem-cell transplantation are mediated not through direct cellular engraftment but rather through extracellular vesicles, cytokines, growth factors, and bioactive peptides released into the surrounding microenvironment [55]. MSC-derived secretomes contain regulatory molecules capable of modulating inflammation, fibrosis, apoptosis, oxidative stress, angiogenesis, and tissue remodeling within reproductive tissues. In ovarian models of chemotherapy-induced injury and premature ovarian insufficiency, peptide-rich secretomes have demonstrated the capacity to improve granulosa-cell survival, restore follicular architecture, reduce inflammatory cytokine signaling, and enhance ovarian endocrine activity [56]. Secretome-derived peptides additionally appear capable of improving endometrial receptivity by promoting vascular remodeling, epithelial repair, and immune tolerance within the implantation microenvironment. Because these regenerative effects can potentially be achieved without direct stem-cell transplantation, peptide-rich secretome therapies represent a promising cell-free regenerative strategy for restoring reproductive tissue homeostasis while minimizing the risks associated with cellular therapies [57]. Collectively, these findings suggest that peptide-based therapeutics may exert reproductive benefits through simultaneous modulation of endocrine signaling, mitochondrial bioenergetics, vascular integrity, and regenerative pathways. Such multi-target biological activity is particularly relevant given the systems-level nature of female infertility, in which mitochondrial dysfunction, oxidative stress, inflammation, endocrine dysregulation, and impaired tissue repair frequently coexist [58]. By targeting these interconnected mechanisms simultaneously, peptide therapeutics may offer a more physiologically integrated and potentially restorative approach to female reproductive medicine than conventional symptom-directed interventions.

Translational Evidence

Experimental studies increasingly support the translational potential of peptide-based therapeutics in female reproductive medicine. Mitochondrial-derived peptides including humanin and MOTS-c have demonstrated protective effects against oxidative stress, mitochondrial dysfunction, apoptosis, and metabolic dysregulation in ovarian and embryonic tissues [51]. Animal studies suggest that mitochondrial peptides improve oocyte maturation, embryo quality, ovarian reserve preservation, and resistance to age-associated reproductive decline [59]. In models of premature ovarian insufficiency, peptide-mediated activation of AMPK and mitochondrial biogenesis pathways has been associated with improved follicular survival and reduced granulosa-cell apoptosis [5]. MSC secretome studies further demonstrate that peptide-rich conditioned media can improve ovarian function, reduce fibrosis, enhance angiogenesis, and restore endocrine signaling following chemotherapy-induced ovarian injury [60].

Recent investigations conducted within regenerative medicine frameworks, including studies associated with the EW Biomedical Group, have explored organ-specific peptide formulations targeting ovarian, hypothalamic, pituitary, adrenal, and mitochondrial pathways relevant to female reproductive aging. These peptide complexes are proposed to modulate gene expression, endocrine balance, mitochondrial bioenergetics, and cellular repair mechanisms associated with ovarian decline and menopausal transition. Preliminary observational findings suggest improvements in hormonal balance, ovarian responsiveness, metabolic function, and systemic vitality. These approaches center on the use of organ-specific peptide bioregulators, mitochondrial-derived peptide complexes, and multi-factorial peptide formulations designed to modulate the interconnected endocrine, metabolic, mitochondrial, and regenerative pathways involved in female fertility. Analogous to applications in male reproductive medicine, these peptide formulations are derived from ultrafiltrates of specific tissues, i.e., hypothalamic, pituitary, ovarian, adrenal, placental, and mitochondrial sources, and are proposed to exert organotrophic regulatory effects through modulation of gene expression, cellular metabolism, and tissue-specific signaling pathways [61].

EW protocols have focused particularly on restoring HPO axis balance, improving ovarian bioenergetics, enhancing microvascular support, and attenuating age-associated reproductive decline. Multi-factorial peptide formulations (MF+) incorporating ovarian, pituitary, hypothalamic, adrenal, and placental peptide complexes have been proposed as biologically integrated interventions aimed at addressing the systems-level nature of female infertility and ovarian aging. Mechanistically, these peptide bioregulators are hypothesized to influence transcriptional programs involved in mitochondrial biogenesis, steroidogenesis, angiogenesis, oxidative stress resilience, and cellular repair. Such effects are biologically plausible given the central role of mitochondrial dysfunction, endocrine dysregulation, vascular insufficiency, and inflammatory signaling in ovarian senescence and diminished reproductive competence [62]. EW regenerative frameworks have additionally emphasized the integration of peptide signaling with precursor stem-cell and secretome-based therapies targeting ovarian rejuvenation and endocrine restoration. Experimental and observational reports suggest that peptide-rich regenerative biologics may improve hormonal balance, ovarian responsiveness, systemic metabolic function, and tissue vitality in women experiencing reproductive aging or menopausal transition.[1] Although these findings remain preliminary, they align mechanistically with broader evidence demonstrating that mitochondrial-derived peptides such as MOTS-c and humanin regulate AMPK, oxidative phosphorylation efficiency, and cellular stress-response pathways implicated in ovarian aging and follicular decline [51]. Furthermore, peptide-mediated enhancement of VEGF signaling and endothelial remodeling may support ovarian and endometrial perfusion, thereby improving follicular oxygenation and implantation-related microenvironmental integrity [63].

The EW approach conceptualizes peptide therapeutics not as

isolated hormonal substitutes but as signaling-level modulators capable of restoring physiological regulatory networks governing reproductive homeostasis. This systems-biology framework is particularly relevant in female infertility, where mitochondrial dysfunction, endocrine imbalance, chronic inflammation, metabolic dysregulation, and impaired tissue regeneration frequently coexist and interact dynamically. Nevertheless, despite promising translational observations, current evidence supporting these interventions remains limited by the predominance of observational studies, heterogeneous peptide formulations, small patient cohorts, and absence of randomized controlled trials. Consequently, rigorous clinical investigation, i.e., standardized peptide characterization, pharmacodynamic profiling, reproductive outcome analysis, and long-term safety evaluation, will be essential before peptide-based regenerative therapies can be fully integrated into evidence-based reproductive medicine.

Safety and Regulatory Considerations

Although peptide therapeutics are generally regarded as biologically compatible due to their endogenous amino-acid composition, important safety considerations remain. Potential risks include immunogenicity, off-target receptor activation, endocrine overstimulation, metabolic dysregulation, and unanticipated effects on embryogenesis or fetal development. Particularly important in reproductive medicine is the possibility of epigenetic modification within germ cells or early embryos. Because peptide interventions may influence mitochondrial function, chromatin remodeling, transcriptional regulation, and cellular metabolism, rigorous long-term reproductive safety evaluation is essential. The heterogeneity of peptide formulations, particularly organ-derived peptide complexes and secretome-based biologics, further complicates regulatory standardization, manufacturing quality control, and pharmacodynamic characterization. Consequently, future clinical translation will require rigorously designed randomized trials, standardized peptide profiling, reproductive toxicology studies, and long-term offspring monitoring.

European Wellness Integrative Fertility Restoration Framework

Female infertility is increasingly recognized as a systems-level disorder involving simultaneous disruption of endocrine regulation, mitochondrial bioenergetics, vascular function, immune homeostasis, and regenerative capacity. Accordingly, EW has developed a multi-modal fertility restoration framework integrating organ-specific peptide bioregulators, MOPs, precursor stem-cell therapies, peptide-rich secretomes, endocrine optimization, and regenerative rehabilitation strategies. Ovarian dysfunction is viewed as a manifestation of broader biological aging rather than an isolated reproductive disorder. Therapeutic objectives therefore extend beyond ovulation induction to include restoration of mitochondrial function, enhancement of tissue repair mechanisms, optimization of HPO-axis communication, and improvement of systemic metabolic resilience. Such an approach aligns with emerging concepts in regenerative reproductive medicine emphasizing restoration of physiological homeostasis rather than symptomatic intervention.

Conclusion

Female infertility arises from complex interactions among endocrine dysregulation, mitochondrial dysfunction, oxidative stress, inflammation, vascular impairment, metabolic disturbance, and reproductive aging. Peptide-based therapeutics represent a promising class of biologic regulators capable of modulating many of these interconnected systems simultaneously. By targeting mitochondrial metabolism, endocrine signaling, angiogenesis, inflammatory pathways, and regenerative signaling networks, peptides offer a mechanistically sophisticated and potentially restorative approach to female reproductive medicine. Advances in peptide biotechnology, mitochondrial therapeutics, regenerative medicine, nano-delivery systems, and precision reproductive diagnostics are rapidly expanding the translational potential of peptide-based interventions. Nevertheless, substantial challenges remain regarding clinical validation, safety characterization, regulatory standardization, and demonstration of meaningful reproductive outcomes. Continued interdisciplinary research integrating reproductive endocrinology, mitochondrial biology, peptide pharmacology, regenerative medicine, and systems biology will be essential to determine whether peptide therapeutics can ultimately transform the treatment paradigm for female infertility.

Competing of Interests

None.

Acknowledgements

None.

References

1. Liu J, Qin Y, Liu H (2025) Global, regional, and national burden of female infertility and trends from 1990 to 2021 with projections to 2050 based on the GBD 2021 analysis. Sci Rep 15(1): 17559.
2. Adebeisi O, Singh M, Tobler K (2026) Female Infertility. Published online April 12.
3. Guzzo KB, Broussard K (2026) Women's Reproductive Health Conditions and Fertility Goals. Popul Res Policy Rev 45(2): 10.
4. Aitken RJ (2024) What is driving the global decline of human fertility? Need for a multidisciplinary approach to the underlying mechanisms. Front Reprod Health 6: 1364352.
5. Li H, Zhu X, Ju R (2025) Mechanisms and treatment modalities related to premature ovarian insufficiency in mitochondria: literature review. J Ovarian Res 19(1): 11.
6. Athar F, Karmani M, Templeman NM (2024) Metabolic hormones are integral regulators of female reproductive health and function. Biosci Rep 44(1): BSR20231916.
7. Orlowski M, Sarao M (2023) Physiology, Follicle Stimulating Hormone. Published online May 1.
8. Contestabile M, Marzi I, Mangione C, Franzoni F, Artini PG, et al. (2026) Endometriosis and Oocyte Quality: Morphological Alterations, Developmental Competence, and Modifiable Strategies for Reproductive Longevity. Cells 15(3): 296.

9. Wang T, Xu P, Yuan (2025) Mitochondrial dysfunction in oocytes: implications for fertility and ageing. J Ovarian Res 18(1): 186.
10. Mihalas BP, Marston AL, Wu LE, Gilchrist RB (2024) Reproductive Ageing: Metabolic contribution to age-related chromosome mis segregation in mammalian oocytes. Reproduction 168(2): e230510.
11. Almansa Ordonez A, Bellido R, Vassena R, Barragan M, Zambelli F (2020) Oxidative Stress in Reproduction: A Mitochondrial Perspective. Biology 9(9): 269.
12. Kobayashi H, Imanaka S (2024) Mitochondrial DNA Damage and Its Repair Mechanisms in Aging Oocytes. Int J Mol Sci 25(23): 13144.
13. Zhang X, Zhang L, Xiang W (2025) The impact of mitochondrial dysfunction on ovarian aging. J Transl Med 23(1): 211.
14. Orisaka M, Mizutani T, Miyazaki Y (2023) Chronic low-grade inflammation and ovarian dysfunction in women with polycystic ovarian syndrome, endometriosis, and aging. Front Endocrinol 14: 1324429.
15. Zhou WJ, Yang HL, Shao J (2019) Anti-inflammatory cytokines in endometriosis. Cell Mol Life Sci CMLS 76(11): 2111-2132.
16. Rathod S, Shanoo A, Acharya N (2024) Endometriosis: A Comprehensive Exploration of Inflammatory Mechanisms and Fertility Implications. Cureus 16(8): e66128.
17. Tricotteaux Zarqaoui S, Lahimer M, Abou Diwan M (2024) Endocrine disruptor chemicals exposure and female fertility declining: from pathophysiology to epigenetic risks. Front Public Health 12: 1466967.
18. Schüler Toprak S, Ortmann O, Buechler C, Treeck O (2022) The Complex Roles of Adipokines in Polycystic Ovary Syndrome and Endometriosis. Biomedicines 10(10): 2503.
19. Sharma M, Balasundaram P (2023) Ovulation Induction Techniques. Published online June 8.
20. Méndez Vidal C, Fernández Sánchez M, Domínguez Moreno M, García Díaz L, Dopazo J, et al. (2026) Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence. Front Reprod Health 8: 1787867.
21. Gupta A, Lu E, Thayer Z (2024) The influence of assisted reproductive technologies-related stressors and social support on perceived stress and depression. BMC Women's Health 24(1): 431.
22. Han Y, Zhang Y, Li H, Ma Z, Wang Y (2025) Peptide Drug: Design and Clinical Applications. MedComm 6(8): e70287.
23. Liu M, Svirskis D, Proft T (2025) Progress in peptide and protein therapeutics: Challenges and strategies. Acta Pharm Sin B 15(12): 6342-6381.
24. Zhao H, Dinh TH, Wang Y, Yang Y. (2025) The roles of MAPK signaling pathway in ovarian folliculogenesis. J Ovarian Res 18(1): 152.
25. Chen J, Liu B, Yao X (2025) AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies from Energy Homeostasis Regulation to Disease Therapy. CNS Neurosci Ther 31(11): e70657.
26. Chan MKS, Wong MB, Nalapko Y, Casazza K, Jonathan RT, et al. (2025) Beyond the Powerhouse: Mitochondrial Organelles as Master Regulators of Wellness. Am J Biomed Sci Res 27(3).
27. Yemeliyanova M, Chan MKS, Wong MBF, Klokol, Dmytro (2024) Unexplained infertility: a fresh look at the old problem and the novel therapeutic options of its treatment. Obstet Gynecol Int J 15(1).
28. Valera H, Chen A, Grive KJ (2025) The Hypothalamic-Pituitary-Ovarian Axis, Ovarian Disorders, and Brain Aging. Endocrinology 166(10): bqaf137.
29. Maeques P, De Sousa Lages A, Skorupskaite K (2024) Physiology of GnRH and Gonadotrophin Secretion. Endotext [Internet]. Updated Oct 15.
30. Tsutsumi R, Webster NJG (2009) GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr J 56(6): 729-737.
31. Ozawa H (2022) Kisspeptin neurons as an integration center of reproductive regulation: Observation of reproductive function based on a new concept of reproductive regulatory nervous system. Reprod Med Biol 21(1): e12419.
32. Houston EJ, Templeman NM (2025) Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J Endocrinol 265(2): e240269.
33. Song J, Xiao L, Zhang Z (2024) Effects of reactive oxygen species and mitochondrial dysfunction on reproductive aging. Front Cell Dev Biol 12: 1347286.
34. Voros C, Athanasiou D, Papapanagiotou I (2025) Cracking the Code of Oocyte Quality: The Oxidative Stress Link to IVF Success. Int J Mol Sci 26(13): 6377.
35. Nur Azan NI, Abdul Karim N, Sulaiman N (2026) Oxidative Stress and Mitochondrial Dysfunction in Cardiovascular Aging: Current Insights and Therapeutic Advances. Biomedicines 14(1): 100.
36. Gałęska E, Kowalczyk A, Wrzecińska M (2025) The Importance of Mitochondrial Processes in the Maturation and Acquisition of Competences of Oocytes and Embryo Culture. Int J Mol Sci 26(9): 4098.
37. May-Panloup P, Boguenet M, Hachem HE, Bouet PE, Reynier P (2021) Embryo and Its Mitochondria. Antioxidants 10(2): 139.
38. Signes A, Fernandez Vizarra E (2018) Assembly of mammalian oxidative phosphorylation complexes I-V and supercomplexes. Essays Biochem 62(3): 255-270.
39. Chiang JL, Shukla P, Pagidas K (2020) Mitochondria in Ovarian Aging and Reproductive Longevity. Ageing Res Rev 63:101168.
40. Patergnani S, Bouhamida E, Leo S, Pinton P, Rimessi A (2021) Mitochondrial Oxidative Stress and "Mito-Inflammation": Actors in the Diseases. Biomedicines 9(2): 216.
41. Pittman MN, Nelsen MB, Thompson MK, Prakash A (2026) Mitochondrial DNA Instability and Neuroinflammation: Connecting the Dots Between Base Excision Repair and Neurodegenerative Disease. Genes 17(1): 82.
42. Ju W, Zhao Y, Yu Y, Zhao S, Xiang S, et al. (2024) Mechanisms of mitochondrial dysfunction in ovarian aging and potential interventions. Front Endocrinol 15: 1361289.
43. Kowalczyk P, Sulejczak D, Kleczkowska P (2021) Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int J Mol Sci 22(24): 13384.
44. Zhang X, Gao Y, Zhang S (2025) Mitochondrial dysfunction in the regulation of aging and aging-related diseases. Cell Commun Signal CCS 23(1): 290.
45. Ma S, Li G, Qin Y (2025) Mitochondrial dysfunction in ovarian aging. Chin Med J (Engl) 138(23): 3069-3082.
46. Huang Y, Liu Z, Geng Y (2025) The risk factors, pathogenesis and treatment of premature ovarian insufficiency. J Ovarian Res18(1): 134.
47. Xiao K, Liu C, Tu Z (2020) Activation of the NF-κB and MAPK Signaling Pathways Contributes to the Inflammatory Responses, but Not Cell Injury, in IPEC-1 Cells Challenged with Hydrogen Peroxide. Oxid Med Cell Longev 2020: 5803639.
48. Chan MKS, Wong MB, Nalapko Y, Klokol, Jonathan RT, et al. (2025) Klotho a Key Player in the Diseasome of Aging. Am J Biomed Sci Res 25(2).
49. Chan M, Wong M, Nalapko Y (2025) Beyond the Kidney-Klotho and the Cardiovascular System. Am J Biomed Sci Res 25(6).
50. Chan M, Wong M, Nalapko Y (2025) Klotho, Obesity, and Inflammation: A Triad of Metabolic Regulation. Am J Biomed Sci Res 25(6).

51. Wan W, Zhang L, Lin Y (2023) Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med 21(1): 36.

52. Guo X, Yi H, Li TC, Wang Y, Wang H, et al. (2021) Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications. Biomolecules 11(2): 253.

53. Demidova Rice TN, Geevarghese A, Herman IM (2011) Bioactive peptides derived from vascular endothelial cell extracellular matrices promote microvascular morphogenesis and wound healing *in vitro*. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc 19(1): 59-70.

54. Chan MK, Wong MB, Nalapko Y (2025) Short-Peptides May Be the Key to Long Life. Am J Biomed Sci Res 26(2).

55. Jarrige M, Frank E, Herardot E (2021) The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. Cells 10(2): 240.

56. Kawilarang S, Wiratnaya IGE, Yasa IWPS, Budiana ING (2025) The role of secretome in restoring ovarian function: A systematic review and meta-analysis of *in vivo* studies in mice with premature ovarian insufficiency. Turk J Obstet Gynecol 22(2): 163-169.

57. Prado Yupanqui JW, Ramírez Orrego L, Cortez D (2025) The Hidden Power of the Secretome: Therapeutic Potential on Wound Healing and Cell-Free Regenerative Medicine-A Systematic Review. Int J Mol Sci 26(5): 1926.

58. Ju W, Yan B, Li D, Lian F, Xiang S (2025) Mitochondria-driven inflammation: a new frontier in ovarian ageing. J Transl Med 23(1): 1005.

59. Xiong D, Zhang Y, Wei J (2026) SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism. J Ovarian Res 19(1): 78.

60. Kavaldzhieva K, Mladenov N, Markova M, Belemezova K (2025) Mesenchymal Stem Cell Secretome: Potential Applications in Human Infertility Caused by Hormonal Imbalance, External Damage, or Immune Factors. Biomedicines 13(3): 586.

61. Bdeir R, Al Keilani MS, Khamaiseh K (2024) Effects of the Neuropeptides Pituitary Adenylate Cyclase Activating Polypeptide and Vasoactive Intestinal Peptide in Male Fertility. Medicina (Mex) 60(4): 652.

62. Kobayashi H, Nishio M, Umetani M, Shigetomi H, Imanaka S, et al. (2025) Endometrial Aging and Reproductive Decline: The Central Role of Mitochondrial Dysfunction. Int J Mol Sci 26(11): 5060.

63. Jankowska Ziemak H, Kulus M, Partynska A (2025) The Role of Growth Factors and Signaling Pathways in Ovarian Angiogenesis. Cells 14(19): 1555.